Alana Lee Grajewski, MD
Ophthalmology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Offices
- 2
Offices
2 locations · Stanford Health Care · Geisinger Clinic
Looking this up.
Hospitals listed: Geisinger Medical Center. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Grajewski’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
State licence records
1 licence
- Florida ME50567Medical Doctor · since 1987 · expires 2026-01-31ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
3 placements
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- Ophthalmology
Education
- Chicago Medical School · MD1980–1983Medical school
Residency and fellowship
- Bascom Palmer Eye Institute, OtherMIAMI, FL · 1987–1989
- Wills Eye Hospital, OphthalmologyPHILADELPHIA, PA · 1984–1987
- University of California, Internal MedicineLOS ANGELES, CA · 1983–1984
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Geisinger Medical CenterDanville, PAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Geisinger, which runs 9 hospitalsPatients rate it 4 of 5 · 72% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 13.4 (11.4 to 15.7) · 748 cases, Jan 2024 – Dec 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.547, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.525, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.6 to 0.9) · 1,370 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Geisinger Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 3 better, 4 the same, 1 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (11.4 to 15.7) · 748 cases | Worse | Jan 2024 – Dec 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.547 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.525 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 0.9) · 1,370 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.82 (1.05 to 2.59) · 2,867 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.97 (0.75 to 1.18) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 208.1 (171.05 to 245.16) · 243 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.5 · 121 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 147 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 280 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.2 · 491 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.6 · 500 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.5 · 577 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 6,518 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0.02 to 0.37) · 11,450 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.03 to 0.38) · 11,860 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.81 (1.26 to 4.36) · 3,644 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.89 (0 to 2.16) · 1,657 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.25 (0.13 to 2.37) · 3,418 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.37 (4.5 to 12.24) · 1,638 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.36 (1.85 to 6.87) · 1,597 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.51 (0.22 to 2.81) · 907 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.97 (0.53 to 1.41) · 9,906 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.9 · 69 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.786 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.65 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.537 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.015 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.5 · 640 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23.7 · 993 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 16 · 356 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 40.8 · 572 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.5 · 548 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.9 · 913 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.6 (3.5 to 6) · 748 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.6 · 67 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 164 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.6 · 356 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.6 (10.8 to 16.9) · 2,820 cases | No different | Jan 2022 – Dec 2024 |
What patients said (2,760 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 78% |
| Nurses "always" listened carefully | 80% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 72% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Medicaid work
$1,349 in 2019
Medicaid paid $1,349 for 34 billed services this clinician did in 2019, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 34 | $1,349 |
| 2019 | 34 | 1 | 14 | $1,349 |
Drugs they prescribed that Part D paid
$13,911
Pharmacies billed $13,911 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 109) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
75 generic and 34 brand-name prescriptions · $13,911 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Timolol Maleate | 13 | $308 | $24 |
| Latanoprost | 27 | $282 | $10 |
| Dorzolamide-Timolol | 13 | $184 | $14 |
Year by year
| 2024 | 109 | 51 | 0% (0) | 31% | $13,911 |
| 2023 | 772 | 135 | 0% (0) | 40% | $106,697 |
| 2022 | 1,004 | 163 | 0% (0) | 43% | $142,068 |
| 2021 | 1,207 | 186 | 0% (0) | 45% | $175,640 |
| 2020 | 1,468 | 229 | 0% (0) | 42% | $224,945 |
| 2019 | 1,509 | 253 | 0% (0) | 42% | $212,290 |
| 2018 | 1,655 | 270 | 0% (0) | 42% | $195,014 |
| 2017 | 2,018 | 292 | None | 42% | $225,607 |
| 2016 | 1,389 | 255 | None | 44% | $136,072 |
| 2015 | 612 | 136 | 0% (0) | 51% | $49,014 |
| 2014 | 821 | 164 | 0% (0) | 56% | $64,072 |
| 2013 | 1,271 | 214 | None | 59% | $90,405 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Restasis | 20 | $12,899 | $645 |
| Lumigan | 35 | $10,989 | $314 |
| Zioptan | 16 | $8,943 | $559 |
| Vyzulta | 16 | $7,307 | $457 |
| Brinzolamide | 25 | $7,108 | $284 |
| Travoprost | 23 | $4,870 | $212 |
| Azopt | 12 | $4,674 | $389 |
| Dorzolamide-Timolol | 125 | $4,333 | $35 |
| Cosopt Pf | 14 | $4,310 | $308 |
| Latanoprost | 204 | $4,124 | $20 |
| Timolol Maleate | 99 | $3,987 | $40 |
| Methazolamide | 14 | $3,475 | $248 |
| Dorzolamide | 35 | $1,434 | $41 |
| Prednisolone Acetate | 15 | $835 | $56 |
| Brimonidine | 41 | $749 | $18 |
2022: 19 drugs
| Lumigan | 49 | $17,496 | $357 |
| Restasis | 15 | $11,419 | $761 |
| Azopt | 27 | $10,232 | $379 |
| Combigan | 15 | $10,070 | $671 |
| Methazolamide | 25 | $9,262 | $370 |
| Zioptan | 16 | $8,553 | $535 |
| Tobradex | 33 | $8,327 | $252 |
| Travoprost | 45 | $8,111 | $180 |
| Dorzolamide-Timolol | 163 | $7,287 | $45 |
| Cosopt Pf | 29 | $6,074 | $209 |
| Latanoprost | 244 | $5,992 | $25 |
| Vyzulta | 14 | $5,864 | $419 |
| Timolol Maleate | 94 | $5,008 | $53 |
| Alphagan P | 11 | $4,797 | $436 |
| Brinzolamide | 14 | $4,154 | $297 |
| Prednisolone Acetate | 35 | $1,892 | $54 |
| Dorzolamide | 40 | $1,430 | $36 |
| Brimonidine | 56 | $1,206 | $22 |
| Neomycin-Polymyxin-Dexameth | 19 | $263 | $14 |
2021: 19 drugs
| Lumigan | 55 | $20,431 | $371 |
| Combigan | 39 | $15,890 | $407 |
| Zioptan | 35 | $15,135 | $432 |
| Azopt | 33 | $14,127 | $428 |
| Dorzolamide-Timolol | 198 | $13,824 | $70 |
| Travoprost | 41 | $9,713 | $237 |
| Methazolamide | 15 | $8,796 | $586 |
| Cosopt Pf | 42 | $8,439 | $201 |
| Latanoprost | 289 | $7,353 | $25 |
| Vyzulta | 16 | $6,995 | $437 |
| Alphagan P | 25 | $6,976 | $279 |
| Restasis | 11 | $6,811 | $619 |
| Tobradex | 25 | $6,513 | $261 |
| Timolol Maleate | 135 | $6,465 | $48 |
| Dorzolamide | 41 | $2,046 | $50 |
| Prednisolone Acetate | 33 | $1,555 | $47 |
| Brimonidine | 57 | $1,473 | $26 |
| Atropine Sulfate | 18 | $896 | $50 |
| Neomycin-Polymyxin-Dexameth | 14 | $167 | $12 |
2020: 20 drugs
| Combigan | 59 | $21,075 | $357 |
| Lumigan | 50 | $20,936 | $419 |
| Azopt | 37 | $17,016 | $460 |
| Zioptan | 49 | $16,079 | $328 |
| Dorzolamide-Timolol | 246 | $15,012 | $61 |
| Rhopressa | 43 | $14,654 | $341 |
| Travatan Z | 36 | $14,193 | $394 |
| Travoprost | 60 | $13,891 | $232 |
| Cosopt Pf | 41 | $13,436 | $328 |
| Restasis | 16 | $13,028 | $814 |
| Timolol Maleate | 167 | $11,634 | $70 |
| Alphagan P | 41 | $11,145 | $272 |
| Latanoprost | 296 | $7,532 | $25 |
| Methazolamide | 13 | $7,317 | $563 |
| Rocklatan | 19 | $6,248 | $329 |
| Dorzolamide | 73 | $3,788 | $52 |
| Vyzulta | 12 | $3,446 | $287 |
| Brimonidine | 89 | $3,089 | $35 |
| Prednisolone Acetate | 21 | $1,006 | $48 |
| Neomycin-Polymyxin-Dexameth | 21 | $372 | $18 |
2019: 23 drugs
| Lumigan | 75 | $23,762 | $317 |
| Combigan | 50 | $18,621 | $372 |
| Travatan Z | 59 | $17,388 | $295 |
| Restasis | 24 | $17,159 | $715 |
| Alphagan P | 46 | $15,251 | $332 |
| Rhopressa | 45 | $13,571 | $302 |
| Methazolamide | 27 | $13,201 | $489 |
| Dorzolamide-Timolol | 181 | $13,053 | $72 |
| Azopt | 37 | $12,984 | $351 |
| Zioptan | 27 | $11,552 | $428 |
| Timolol Maleate | 171 | $9,133 | $53 |
| Cosopt Pf | 36 | $8,111 | $225 |
| Latanoprost | 311 | $7,103 | $23 |
| Rocklatan | 24 | $6,737 | $281 |
| Brimonidine | 94 | $4,414 | $47 |
| Vyzulta | 11 | $3,781 | $344 |
| Dorzolamide | 65 | $2,730 | $42 |
| Prednisolone Acetate | 57 | $2,471 | $43 |
| Simbrinza | 15 | $2,409 | $161 |
| Neomycin-Polymyxin-Dexameth | 48 | $704 | $15 |
| Olopatadine | 14 | $521 | $37 |
| Atropine Sulfate | 11 | $520 | $47 |
| Erythromycin | 17 | $257 | $15 |
2018: 18 drugs
| Lumigan | 83 | $25,286 | $305 |
| Azopt | 67 | $21,363 | $319 |
| Timolol Maleate | 222 | $19,736 | $89 |
| Travatan Z | 65 | $19,140 | $294 |
| Methazolamide | 31 | $13,682 | $441 |
| Combigan | 35 | $13,521 | $386 |
| Alphagan P | 47 | $11,872 | $253 |
| Zioptan | 26 | $8,863 | $341 |
| Brimonidine | 134 | $8,451 | $63 |
| Latanoprost | 406 | $8,216 | $20 |
| Cosopt Pf | 29 | $7,358 | $254 |
| Dorzolamide-Timolol | 186 | $5,000 | $27 |
| Prednisolone Acetate | 60 | $3,180 | $53 |
| Simbrinza | 14 | $2,793 | $199 |
| Dorzolamide | 89 | $1,988 | $22 |
| Ketorolac Tromethamine | 13 | $312 | $24 |
| Neomycin-Polymyxin-Dexameth | 24 | $304 | $13 |
| Erythromycin | 19 | $175 | $9 |
2017: 19 drugs
| Travatan Z | 106 | $30,703 | $290 |
| Methazolamide | 59 | $30,492 | $517 |
| Lumigan | 91 | $22,783 | $250 |
| Azopt | 65 | $18,723 | $288 |
| Alphagan P | 73 | $17,718 | $243 |
| Combigan | 54 | $15,771 | $292 |
| Timolol Maleate | 225 | $13,898 | $62 |
| Zioptan | 57 | $12,038 | $211 |
| Brimonidine | 153 | $11,476 | $75 |
| Dorzolamide-Timolol | 344 | $8,476 | $25 |
| Latanoprost | 417 | $7,142 | $17 |
| Cosopt Pf | 25 | $6,799 | $272 |
| Prednisolone Acetate | 99 | $5,712 | $58 |
| Simbrinza | 24 | $3,429 | $143 |
| Pataday | 12 | $2,871 | $239 |
| Dorzolamide | 76 | $1,559 | $21 |
| Phospholine Iodide | 14 | $1,280 | $91 |
| Neomycin-Polymyxin-Dexameth | 28 | $402 | $14 |
| Erythromycin | 18 | $192 | $11 |
2016: 17 drugs
| Methazolamide | 50 | $24,647 | $493 |
| Travatan Z | 63 | $14,740 | $234 |
| Combigan | 64 | $14,702 | $230 |
| Lumigan | 49 | $11,409 | $233 |
| Timolol Maleate | 165 | $11,048 | $67 |
| Azopt | 37 | $11,029 | $298 |
| Brimonidine | 106 | $6,888 | $65 |
| Prednisolone Acetate | 99 | $4,958 | $50 |
| Dorzolamide-Timolol | 246 | $4,834 | $20 |
| Alphagan P | 21 | $4,786 | $228 |
| Zioptan | 19 | $4,013 | $211 |
| Latanoprost | 255 | $3,888 | $15 |
| Lotemax | 16 | $3,207 | $200 |
| Simbrinza | 23 | $3,185 | $138 |
| Dorzolamide | 72 | $1,864 | $26 |
| Neomycin-Polymyxin-Dexameth | 13 | $216 | $17 |
| Erythromycin | 16 | $145 | $9 |
2015: 13 drugs
| Timolol Maleate | 75 | $6,638 | $89 |
| Methazolamide | 12 | $5,696 | $475 |
| Lumigan | 22 | $4,252 | $193 |
| Prednisolone Acetate | 72 | $3,719 | $52 |
| Travatan Z | 18 | $3,039 | $169 |
| Combigan | 15 | $2,647 | $176 |
| Azopt | 11 | $2,576 | $234 |
| Zioptan | 18 | $2,347 | $130 |
| Cosopt Pf | 15 | $2,287 | $152 |
| Dorzolamide-Timolol | 89 | $1,914 | $22 |
| Latanoprost | 117 | $1,652 | $14 |
| Brimonidine | 40 | $1,522 | $38 |
| Dorzolamide | 34 | $724 | $21 |
2014: 13 drugs
| Travatan Z | 77 | $11,260 | $146 |
| Timolol Maleate | 109 | $6,465 | $59 |
| Methazolamide | 18 | $6,317 | $351 |
| Latanoprost | 183 | $3,703 | $20 |
| Brimonidine | 39 | $3,614 | $93 |
| Prednisolone Acetate | 60 | $3,555 | $59 |
| Zioptan | 29 | $3,343 | $115 |
| Dorzolamide-Timolol | 88 | $2,727 | $31 |
| Lumigan | 20 | $2,684 | $134 |
| Azopt | 12 | $2,494 | $208 |
| Simbrinza | 15 | $1,506 | $100 |
| Dorzolamide | 32 | $1,120 | $35 |
| Erythromycin | 13 | $186 | $14 |
2013: 20 drugs
| Travatan Z | 127 | $18,883 | $149 |
| Timolol Maleate | 194 | $7,507 | $39 |
| Timoptic Ocudose | 19 | $6,343 | $334 |
| Alphagan P | 40 | $6,247 | $156 |
| Latanoprost | 259 | $6,241 | $24 |
| Dorzolamide-Timolol | 137 | $6,172 | $45 |
| Lumigan | 46 | $5,595 | $122 |
| Restasis | 11 | $3,354 | $305 |
| Zioptan | 27 | $3,297 | $122 |
| Methazolamide | 17 | $2,707 | $159 |
| Pataday | 18 | $2,310 | $128 |
| Betoptic S | 11 | $2,012 | $183 |
| Prednisolone Acetate | 78 | $1,691 | $22 |
| Brimonidine | 22 | $1,436 | $65 |
| Cosopt Pf | 16 | $1,431 | $89 |
| Dorzolamide | 35 | $1,165 | $33 |
| Erythromycin | 49 | $823 | $17 |
| Doxycycline Hyclate | 12 | $542 | $45 |
| Neomycin-Polymyxin-Dexameth | 21 | $385 | $18 |
| Carteolol | 16 | $260 | $16 |
Money from drug and device companies
$211 in 2025
| 2025 | 3 | 4 | None | $211 |
| 2024 | 1 | 2 | None | $145 |
| 2023 | 1 | 1 | None | $115 |
| 2021 | 1 | 2 | None | $122 |
| 2020 | 1 | 2 | None | $30 |
| 2019 | 2 | 2 | None | $133 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sight Sciences | Omni Surgical System | $98 | 1 payment
|
| Abbvie | Xen Glaucoma Treatment System | $93 | 2 payments
|
| Bausch & Lomb Americas | Miebo | $20 | 1 payment
|
See all 4 published payments
| Sight Sciences | Meals · 2025-07-15 | Omni Surgical System | $98 |
| Abbvie | Meals · 2025-05-21 | Xen Glaucoma Treatment System | $78 |
| Abbvie | Meals · 2025-05-06 | Durysta | $15 |
| Bausch & Lomb Americas | Meals · 2025-02-10 | Miebo | $20 |
See earlier years (2024, 2023, 2021, 2020, 2019)
2024: $145
| Sight Sciences | Omni Surgical System | $145 | 2 payments
|
2023: $115
| Sight Sciences | Omni Surgical System | $115 | 1 payment
|
2021: $122
| Sight Sciences | Omni(R) Surgical System (US) | $122 | 2 payments
|
2020: $30
| Sight Sciences | Omni | $30 | 2 payments
|
2019: $133
| Aerie Pharmaceuticals | Rhopressa | $122 | 1 payment
|
| Sight Sciences | Omni | $11 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 81.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1538187588
- Licence
- FL ME50567Florida ME50567: Active
- Group
- Stanford Health Care · Geisinger Clinic
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- FM 0617466-00
- Taxonomy
- Federal specialty code 207WX0009X (207WX0009X); Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-07-18
- NPI last updated
- 2025-12-16
- NPI record certified
- 2025-12-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 16 Woodbine Ln, Danville, PA, 17821 · 900 Nw 17th St, Miami, FL, 33136